Navigation Links
Delcath Achieves ISO 13485 Certification
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced that the Company has achieved ISO 13485:2003 Certification—an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union (EU). ISO 13485 Certification is a regulatory requirement of the EU's Medical Device Directive, and represents an important step toward attaining European CE Mark approval for the Company's proprietary Hepatic ChemoSAT™ Delivery System.

Commenting on the announcement, Eamonn P. Hobbs, CEO & President of Delcath Systems, said, "ISO 13485 Certification confirms that our manufacturing and quality systems meet the high standards required of medical device companies selling into Europe, and we are pleased to have achieved this important milestone toward the receipt of CE Mark approval. Our technical file for CE Mark is pending, and we continue to expect CE Mark approval for our product in mid-2011."

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA approval for commercial sale of its system. For more information, please visit the Company's websit
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
2. Delcath Systems Announces Third Quarter Progress Report Conference Call
3. Delcath Strengthens Research and Development Team with Key Appointments
4. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
5. Delcath to Present at the William Blair Emerging Growth Stock Conference
6. Delcath to Present at the JMP Securities Healthcare Conference
7. Delcath Systems Announces Completion of Common Stock Offering
8. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
9. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
10. Delcath Systems Announces Second Quarter Progress Report Conference Call
11. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
(Date:10/20/2014)... 20, 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Surgeons Annual Meeting that they have joined forces ... The collaboration is the first of its kind ... patient outcomes. NICO,s BrainPath® interventional access technology and ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... Mass. , May 5 LightLab Imaging, ... Optical Coherence Tomography (OCT) technology for vascular and other ... and Drug Administration (FDA) for the C7-XR Imaging System ... LightLab,s latest generation Frequency Domain OCT (FD-OCT™) technology, are ...
... May 5 Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) ... Care Conference in New York, New York , on May 11, 2010 , ... , , A live ... .  The webcast will be archived for replay following the conference. , ...
Cached Medicine Technology:LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 2LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 3LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 4Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference 2
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... WEDNESDAY, Dec. 1 (HealthDay News) -- The case of a ... -- and actually got better -- sheds light on how ... suggests. "Our findings in this case report suggest that ... roundworm can alleviate the symptoms of ulcerative colitis," said study ...
... , This release is available in French ... and the brain appear to be even more closely connected ... apparently not confined to the heart, but also affect the ... the level of the brainstem, which leads to insomnia, notably ...
... -- A "virtual biopsy" may help diagnose a degenerative ... others who suffer repeated blows to the head, says ... encephalopathy (CTE) can include memory problems, impulsive and erratic ... marked by an accumulation of abnormal proteins in the ...
... Alex Mitchell, of the Department of Cancer Studies and ... study which has been published in the journal ... screening refers to population based medical tests such as ... detect conditions such as cancer, diabetes or heart ...
... Dec. 1 (HealthDay News) -- A test that measures the ... at an early stage and help doctors evaluate the effectiveness ... as early as possible -- before it destroys the optic ... the researchers, from the Bascom Palmer Eye Institute at the ...
... HealthDay Reporter , TUESDAY, Nov. 30 (HealthDay News) ... directions on the labels of over-the-counter kids, medicines may ... that most of the popular cough-and-cold, pain-relieving, allergy and ... begin with. Nor is there much consistency in product ...
Cached Medicine News:Health News:Worm Therapy Shows Promise for Ulcerative Colitis 2Health News:Worm Therapy Shows Promise for Ulcerative Colitis 3Health News:Insomnia after myocardial infarction 2Health News:Imaging May Reveal Sports-Related Brain Disorder at Early Stage 2Health News:People with mental illness receive inadequate mass screening for prevention of medical conditions 2Health News:Confusing Labeling Found on Many Nonprescription Kids' Meds 2Health News:Confusing Labeling Found on Many Nonprescription Kids' Meds 3
... IMMULITE and IMMULITE 1000 ... with the IMMULITE and IMMULITE ... analyzers which offer simplicity in ... systems can be found in ...
... Anti-Nuclear Antibodies (ANAs) has long been an ... rheumatic diseases. The antigens used in their ... of human or animal nuclei, this has ... Antigens (ENAs). The most commonly measured ENA ...
... Automation, Inc. (DAI) ENA Profile Enzyme-Linked Immunosorbent ... of antibodies in human serum to individually ... Scl-70 and Jo-1 in a single serum ... to be used as an aid in ...
... Enzyme-linked immunosorbent assays for the ... antibodies to extractable nuclear antigens ... Antibodies to Sm aid in ... erythematosus (SLE). ,RNP antibodies aid ...
Medicine Products: